Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Monday 2 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Patients

TMS being given to female patient by female HCP.

TMS works. Why do fewer than 1% of eligible patients get it?

A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.

Digital

Female patient in remote patient monitoring.

Reducing the risk of at-home chemo complications with remote...

Remote patient monitoring (RPM) of vitals takes away the uncertainty of leaving symptom detection to patients.

R&D

Cargo vessels in Straight of Hormuz

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

Oncology

Hengrui exhibition booth at ESMO 2026

Sponsored

Global oncology innovation from Hengrui Pharma

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Articles

A Collaborative Approach to Drug Development

A Collaborative Approach to Drug Development

As Quintiles releases its latest New Health Report, Jeffrey Spaeder looks at the role of patients, payers and physicians in the clinical development process. In order for new therapies to meet the needs of all the stakeholders, an increasing emphasis by the biopharmaceutical industry on early collaborations with...

Articles

QR Codes – applications and innovations for pharma

QR Codes – applications and innovations for pharma

Nick Plank demystifies the area of QR codes and shares how they can be of use in pharma. QR what? Reading this in a recent email from a friend of mine who I have always thought to be super switched on to high-tech and is a...

Articles

Are apps medical devices? Part one: what is the impact on pharma as the first app is registered as medical device with the MHRA?

Are apps medical devices? Part one: what is the impact on ph...

Paul Dixey and Sam Walmsley offer some points to consider when developing an app.

Load more results

Sales & Marketing

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

The dangers of social media for pharma

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Digital

Female patient in remote patient monitoring.

Reducing the risk of at-home chemo complications with remote...

Remote patient monitoring (RPM) of vitals takes away the uncertainty of leaving symptom detection to patients.

Digital

Agentic AI concept

Sponsored

4 Questions pharma leaders can’t skip before letting AI act

Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

UK budget includes £1bn biopharma investment package

HHS doubles down on controversial peptides plan

Lilly's triple G overpowers Ozempic in diabetes trial

UK puts £100m into "world-first" AI biosecurity facility

US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Oncology

Hengrui exhibition booth at ESMO 2026

Sponsored

Global oncology innovation from Hengrui Pharma

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Oncology

AI targeting cancer cell graphic

How AI is advancing patient subgroup identification in oncol...

With the advent of AI, it’s now possible to enrich clinical trials for patient subgroups more precisely than ever before.

Patients

Patients

TMS being given to female patient by female HCP.

TMS works. Why do fewer than 1% of eligible patients get it?

A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.

Patients

HCP talks to patient in clinical trial

Why “rare disease” is a regulatory label, not a patient real...

Regulators define a rare disease by how many people have it, and the answer depends on who is counting.

Patients

pharmaphorum podcast Episode 281 - Cecilia Caetano, Bayer

Sponsored

Menopause is an urgent global health issue: Bayer’s Cecilia ...

R&D

R&D

Cargo vessels in Straight of Hormuz

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

R&D

Auto vacuum sealed vaccines in manufacturing plant

Reliability in life sciences logistics: What good looks like

What constitutes a reliable supply chain is changing rapidly.

R&D

Heart on ECG digital graphic

Cardiovascular disease today: NMR-based lipoprotein profilin...

pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.

Editor's Picks

UK budget includes £1bn biopharma investment package

HHS doubles down on controversial peptides plan

Lilly's triple G overpowers Ozempic in diabetes trial

UK puts £100m into "world-first" AI biosecurity facility

US gives $99m for Ebola jab project, as cases spread in Africa

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company